Filing summary
Entity and period: The supplied filing is Nemus Bioscience, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2016, filed August 12, 2016. It does not identify Skye Bioscience, Inc. as the registrant; investors should verify that this is the intended filing.
Business context
Nemus described itself as an early-stage biopharmaceutical company developing cannabinoid-based therapeutics through a partnership with the University of Mississippi. It reported no revenue from planned principal operations and was focused on licensing, research and development, and building infrastructure.
Financial highlights
| Metric | Q2 2016 / June 30, 2016 | Comparable period / prior balance |
|---|---|---|
| Revenue | None | None in Q2 2015 |
| Operating expenses | $1.48 million | $1.36 million in Q2 2015 |
| Operating loss | $1.48 million | $1.36 million in Q2 2015 |
| Net income (loss) | $573,093 | Loss of $2.06 million in Q2 2015 |
| Six-month net loss | $1.11 million | $2.97 million in first half 2015 |
| Cash and cash equivalents | $831,658 | $3.22 million at December 31, 2015 |
| Six-month operating cash flow | Use of $2.38 million | Use of $1.32 million in first half 2015 |
| Total liabilities | $1.34 million | $3.04 million at December 31, 2015 |
The Q2 profit reflected $2.02 million of noncash income from a decline in the fair value of Series B warrant liabilities and $31,414 of income from a change in the Series B conversion-right valuation. For the first half, the warrant revaluation generated $1.61 million of income, partly offset by $21,814 of conversion-right expense. These valuation changes substantially affected reported earnings; operations remained loss-making.
First-half R&D expense increased to $595,316 from $80,574, while general and administrative expense was $2.11 million versus $2.19 million. The filing reports no interest paid and no material off-balance-sheet arrangements. It does not present conventional borrowings as a material financing source. Series B preferred stock is classified as mezzanine equity, has a $4.5 million liquidation preference, and includes contingent redemption provisions.
Changes, outlook and risks
- Cash fell by approximately $2.39 million in the first half; operating activities used $2.38 million, with no financing proceeds during the period.
- Management said the company expected continuing losses and significant R&D, public-company, and infrastructure costs. Without additional funding, management did not expect available funds to meet obligations within one year after issuance of the financial statements, creating substantial doubt about going concern.
- Management intended to seek equity or debt financing, collaborations, licensing arrangements, asset sales, grants, or other funding, but gave no assurance funding would be available. Equity financing could dilute shareholders; inability to raise funds could force spending cuts, delays, or curtailment of programs.
- Development activities included THC pro-drug process and analytical work with a contract manufacturer, CBD-derivative research for chemotherapy-induced peripheral neuropathy, and a cannabinoid/MRSA research project. The filing cited estimated initial CMO fees of $154,000–$183,000 for process development and $142,900 for analytical work, with further potential costs for sample production and stability studies.
- Operating lease minimum payments totaled $285,222 as of June 30, 2016. UM licenses also carry milestone, royalty, annual-fee, and patent-cost reimbursement obligations; stated aggregate milestone payments are $2.1 million for UM 5050 licenses and $1.4 million for UM 8930 licenses if milestones are achieved.
- The Hollister litigation was dismissed with prejudice in August 2016, with no settlement payment reported. The company identified regulatory uncertainty surrounding cannabis, early-stage development, reliance on UM and third parties, intellectual-property protection, competition, and future financing as risks.
Investor verification priorities
- Confirm the issuer and filing match the intended company: this report names Nemus Bioscience, Inc., not Skye Bioscience, Inc.
- Assess the going-concern warning, cash depletion, subsequent financing activity, and the company’s ability to fund operations.
- Review the Series B preferred stock’s $4.5 million liquidation preference, contingent redemption triggers, and warrant-related valuation sensitivity.
- Verify the status, costs, milestones, and rights under UM licenses, research programs, and the CMO agreement.
- Distinguish reported Q2 net income from underlying operating performance: the quarter’s profit was primarily due to noncash warrant revaluation, while the company had an operating loss and no revenue.